AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca accumulated depreciation & impairment of PP&E ($M) ($M)
Form 20-F Note 8 — PP&E (Inline XBRL)
Latest, FY2025
-9,338
Period ended Dec 31, 2025
Change on a year earlier
+17.1%
-7,971 in FY2024
History
8 years
Since FY2018
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accumulated depreciation & impairment of PP&E ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -9,338 | +17.1% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | -7,971 | +2.0% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | -7,816 | +9.4% | Form 20-F FY2025 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | -7,142 | -8.7% | Form 20-F FY2024 Annual Report ↗ |
| FY2021 | Dec 31, 2021 | -7,825 | +0.1% | Form 20-F FY2024 Annual Report ↗ |
| FY2020 | Dec 31, 2020 | -7,816 | +6.9% | Form 20-F FY2023 Annual Report ↗ |
| FY2019 | Dec 31, 2019 | -7,313 | +1.3% | Form 20-F FY2023 Annual Report ↗ |
| FY2018 | Dec 31, 2018 | -7,218 | – | Form 20-F FY2022 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca Accumulated depreciation & impairment of PP&E ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ppe_accum_depr
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.